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1 Introduction
The 2,3-dihydrobenzofuran (DHB) skeleton 1 comprises a 
saturated 5-membered oxygen heterocycle fused to a benzene 
ring with the oxygen atom adjacent to the aromatic system 
(Fig. 1). This ring system confers a rigid shape to a molecule, 
with a well defined spatial arrangement of substituents in a 
similar manner to strained small rings such as cyclopropanes 
and cyclobutanes. However, the ring-strain in the DHB system 
is moderate, and somewhat smaller than in the corresponding 
dihydrofuran system 2 without the fused benzene ring.1
Many bioactive molecules containing the DHB structural 
motif have been reported including a vast array of natural 
products (selected examples shown in Fig. 2, 3–8)2–7 and 
numerous synthetic compounds with useful biological activity 
(selected examples shown in Fig. 3, 9–14). DHB containing 
natural products have been reported with activity against 
cancer (4–5),2,4,8–10 tuberculosis,11 malaria12 and cataracts,13 as 
well as activity at specific targets such as HIF-1 (8),6 α-
glucosidase,14 aldose reductase,6 5-LOX (7),7 COX-2 (7),7 
NF-κβ4 and the muscarinic M3 receptor.15,16,17 Other DHB natu-
ral products show antioxidant and/or cytoprotective proper-
ties18 and insecticidal activity.19 Figure 1 shows only a fraction 
of the many known DHB natural products — more than 500 
DHB-containing natural products were reported in 2009–2010 
alone. [A Reaxys® search of DHB containing natural products 
reported during this time period produced 562 substance 
hits. Note that this includes previously known structures (re-
isolations, etc) as well as structurally novel natural products.]
It should also be noted that a DHB system forms part of the 
skeleton of the morphine alkaloids, although the synthesis of 
these more complex polycyclic systems will not be considered 
here.
Synthetic DHB derivatives include recently reported mole-
cules such as the GPR4 Agonist 9,20 imidazolium compound 
10 (cytotoxic),21 triazole 11 (antitubercular),22 diester 12 (active 
against leishmaniasis),23 and the drugs Prucalopride 1324 
(treatment of constipation) and Efaroxan 14 (α2-adrenoceptor 
antagonist).25
As a consequence of the diverse biological activities 
displayed by these compounds, synthetic chemists have devel-
oped many effective methods for accessing the DHB skeleton. 
This review article will summarise the different synthetic 
approaches to DHBs, focusing largely on recent reports 
since a previous review of the field in 2009.26 The synthetic 
approaches are classified according to the method by which 
the saturated oxygen ring is constructed.
Plausible synthetic approaches to the DHB skeleton are 
shown in Scheme 1. The most obvious strategy involves a clas-
sical phenol alkylation approach (I, O-alkyl bond formation). 
Alternatively, the O-aryl bond can be constructed via a transi-
tion-metal catalysed cross coupling (II). The direct construc-
tion of the aromatic ring itself (III) is an approach that has 
rarely been applied in DHB synthesis. In contrast, the con-
struction of the C-aryl bond (IV) is a well explored approach 
(e.g. via lithation of an aryl halide). The formation of the alkyl 
C–C bond (V) is commonly achieved via transition-metal 
mediated carbene C–H insertion processes using diazo 
compounds. Finally, more complex strategies involving either 
the formation of two or more bonds in a single reaction (VI), 
or the rearrangement of an existing ring system (VII) can be 
employed.
2 Formation of the O-alkyl bond
The intramolecular alkylation of a phenol is perhaps the 
most common method for the construction of DHBs. Given 
that many natural products contain a hydroxyalkyl group 
This article gives an overview of synthetic approaches to the 2,3-dihydrobenzofuran ring system with an emphasis 
on recently developed methods. The synthetic approaches are classified according to the key bond(s) formed during 
the construction of the dihydrobenzofuran skeleton, and approaches of relevance to the synthesis of natural products 
are highlighted.
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Fig.  1 The structures of 2,3-dihydrobenzofuran (DHB) and 
2,3-dihydrofuran.
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joined to the ring system at C2, the ring opening of an epoxide 
is a particularly useful approach and has been explored 
extensively in recent years. For example, the chiral ketone 15 
was used to access enantioenriched epoxides 17 which gave 
the corresponding DHB derivatives 18 in good yield and 
high ee (Scheme 2), after deprotection of the phenol with 
fluoride.27 This approach was used in the synthesis of the DHB 
containing natural product (+)-marmesin.28
In a similar fashion, Sharpless asymmetric epoxidation of 
allylic alcohols such as 19 gave enantioenriched epoxides 20 
(Scheme 3). Deprotection of the phenol and cyclisation with 
base enabled chiral diol 21 to be synthesised in good yield.29 
This approach was used to access the core structure (22) of 
heliannuols G and H.30
A very similar approach using a Sharpless asymmetric dihy-
droxylation enabled ring systems such as 25 to be synthesised, 
via regioselective monotosylation of the diol 23 (Scheme 4).31 
After protection of the remaining free hydroxyl group, 
DHB formation readily took place upon deprotection of the 
Fig. 2 Selected DHB natural products.
Fig. 3 Some synthetic DHBs with useful biological activity.
Scheme 1 Strategies for DHB synthesis.
Scheme 2 Enantioselective synthesis of DHBs using a 
Shi epoxidation.
Scheme 3 Enantioselective synthesis of DHBs using a 
Sharpless asymmetric epoxidation (SAE).
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phenol and treatment with base. This approach was used to 
synthesise both enantiomers of the core structure 26, present 
in a variety of natural products including Avicenol A32 and 
Brosimacutin G.33
A very common strategy for constructing the DHB ring 
system involves the electrophile-mediated cyclisation of o-
allylphenols (Scheme 5).34–38 Thus, activation of o-allylphenol 
27 with suitable electrophiles can provide access to DHBs 28 
containing halogens,38 thioethers35 or simple alkyl groups34,37 
in the side chain. In a similar vein, Pd-mediated cyclisation 
of propargylic phenols 29 was shown to give access to the exo-
cyclic alkenes 30 which are potentially useful building blocks 
for further elaboration.39
A practical biocatalytic strategy for accessing simple DHBs 
in high ee was recently reported (Scheme 6).40 Two comple-
mentary methods were developed: enantioselective reduction 
of ketone 31 with alcohol dehydrogenase (ADH) and kinetic 
resolution of alcohol 32 with vinyl acetate/Lipase. In both 
cases the resulting enantiopure alcohols 33 were cyclised via a 
Mitsunobu reaction with clean inversion of stereochemistry to 
give the enantiopure DHB products 34.
A catalytic enantioselective DHB formation was recently 
reported using chiral iodide 35 in the presence of tBuOOH for 
the oxidative cyclisation of ketophenols 36 (Scheme 7).41 
A range of DHBs (e.g. 37) could be prepared in excellent ee 
and high yield, with even 2,2-disubstituted products such as 
38 being produced efficiently. The imidazole group could be 
cleaved to give a more synthetically useful ethyl ester without 
loss of ee, by treatment with MeOTf followed by ethanol and 
base. The authors proposed that the chiral cation of 35 directs 
the reaction of a phenolate anion with the ketone, which is 
activated by a hypervalent iodine species generated in situ.
3 Formation of the O-aryl bond
The intramolecular copper or palladium-catalysed coupling of 
an aliphatic alcohol with an aryl halide is an effective strategy 
to access DHB derivatives which was developed several years 
ago.42–45 Surprisingly there have been few recent developments 
in this area, despite the high level of interest in the develop-
ment of novel catalytic methods for aryl-heteroatom bond 
formation. An unusual approach to DHBs via a catalytic intra-
molecular Chan–Lam coupling reaction has recently been 
reported (Scheme 8).46 o-Alkynlbenzeneboronic acids 39 
undergo Au-catalysed enolate formation and aldol reaction to 
give cyclic borates 40. These compounds can be cyclised 
to the corresponding 2,3-disubstituted DHBs 41 containing 
a pendant ketone group at C3 with very good yields over 
this three step reaction process. It is notable that this cross-
coupling reaction involves the arylation of an aliphatic alcohol 
and also only requires catalytic quantities of copper; both of 
these factors being somewhat unusual in Chan-Lam coupling 
reactions.47 This approach is potentially quite versatile as 
variation of the groups at R1 and R2 can easily be achieved 
(e.g. 42–43).
Yu and co-workers recently reported a Pd-mediated C-H 
activation protocol for the direct cyclisation of homo-benzylic 
alcohols 44, which proceeds in high yield to give 2,2-disubsti-
tuted DHBs 45 (Scheme 9).48 These reactions were much 
more efficient for the formation of 2,2-disubstituted DHBs 
(e.g. 46–47), with the corresponding reactions of secondary 
alcohols proceeding in lower yield. Nevertheless, this method-
ology is potentially very powerful as it does not require 
Scheme 4 Enantioselective synthesis of DHBs using a 
Sharpless asymmetric dihydroxylation (AD).
Scheme 5 Synthesis of DHBs via cyclisation of phenols onto 
activated C-C multiple bonds
Scheme 6 Biocatalytic synthesis of enantiopure DHBs.
Scheme 7 Enantioselective oxidative cyclisation of 
ketophenols using a chiral iodide salt.
Scheme 8 Synthesis of DHBs via an intramolecular 
Chan-Lam coupling strategy.
380 JOURNAL OF CHEMICAL RESEARCH 2011
pre-functionalisation of the aromatic ring. It is also compatible 
with the presence of aryl bromides, enabling the construction 
of halogenated DHBs (47) which can then be further elabo-
rated via traditional transition-metal catalysed coupling 
reactions. 
4 Formation of the aromatic ring
The direct formation of the benzene ring has rarely been used 
in the construction of DHBs, despite the fact that Rh-catalysed 
[2+2+2] cycloadditions for the formation of closely related 
fused benzofurans have been reported.49 An iron-mediated 
approach proceeding via the Fe-complexed cyclopentadienone 
49 was reported in 2001 (Scheme 10).50 An alkynyl homo-
propargyl ether, generated from the dichlorovinyl ether 48, 
underwent cyclisation in the presence of iron pentacarbonyl to 
give 49 in moderate yield over the two steps. After oxidative 
decomplexation, the free cyclopentadienone system readily 
undergoes cycloaddition with dimethyl acetylenedicarboxyl-
ate (DMAD) followed by extrusion of CO, to give the 
polysubstituted DHB 50 in moderate yield over two steps. 
This example serves to illustrate how this type of approach 
can be used to construct DHBs containing a highly substituted 
aromatic ring.
5 Formation of the aryl-C3 bond
The formation of the aryl-carbon bond has been used to 
access a number of DHB systems. Chiral ligand 53 was pre-
pared via a reaction sequence which involved the one-pot 
double lithiation/cyclisation/phosphination of tribromide 51 
(Scheme 11).51 The DHB phosphine 52 was obtained in 66% 
yield and was then dimerised to give the racemic bidendate 
ligand 53 which was subsequently resolved by HPLC. Although 
enantioselective reactions of ligand 53 were not reported, 
more recently a different DHB-containing phosphine has 
been employed in enantioselective Pd-catalysed [3+2] 
cyclodaddition reactions.52
Bromoarylalkynes such as 54 were shown to selectively 
undergo trans carbolithiation upon treatment with nBuLi 
(Scheme 12).53 The resulting alkenes 55 are potentially useful 
compounds for further elaboration.
One obvious approach to the construction of the aryl-C3 
bond is to employ a Heck reaction to cyclise an allylic ether of 
an o-halophenol (Scheme 13). This provides a product with an 
unsaturated side chain at C3 which can be exploited in further 
reactions. For example, Heck reaction of aryliodides 56 con-
taining a pendant chiral allylic ether (prepared by asymmetric 
reduction of a cyclohexenone) was shown to give DHBs fused 
to a cyclohexene ring 57, with predominantly cis stereochem-
istry.54 Carbonylative Heck cyclisation of aryldiazonium salts 
58 onto pendant alkenes was shown to give DHBs 59 contain-
ing a carboxylic acid group on the C3 side chain in moderate 
yield.55 Using aryl bromide 60, a series of Pd-catalysed 
tandem cyclisation/coupling reactions were investigated.56 
For example, tandem cyclisation/Stille coupling yielded 
3,3-disubstituted DHB 61 in good yield in the presence of 
1,3-dimethyl-1,2-imidazolidinone (DMI). Tandem Suzuki 
coupling reactions with a range of aryl boronic acids were also 
successful, and these reactions could even be combined with 
the preparation of 60 in situ by alkylation of the parent phenol. 
Very recently, a potentially useful procedure for Heck cyclisa-
tion and concomitant cyanation was reported.57 Treatment of 
Scheme 9 Synthesis of DHBs via C-H activation of 
homo-benzylic alcohols.
Scheme 10 Iron-mediated cycloaddition route to a highly 
substituted DHB.
Scheme 11 Formation of a DHB chiral ligand via a lithiation 
strategy.
Scheme 12 A trans-selective intramolecular carbolithiation.
Scheme 13 Synthesis of DHBs via Heck reaction.
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methallyl ether 62 with palladium acetate in the presence 
of K4Fe(CN)6 as a cyanide source led to the formation of a 3,3-
disubstituted DHB 63 containing a cyanomethyl substituent at 
C3 in moderate yield.
6 Formation of the alkyl C2–C3 bond
Surprisingly, one of the most common approaches to the syn-
thesis of DHBs has been the formation of the alkyl C2–C3 bond. 
The most widely used approach exploits the asymmetric 
carbene C–H insertion reactions originally developed by 
Davies.58–60 These reactions proceed with high stereoselectiv-
ity and through the use of chiral ligands and/or a chiral auxil-
iary,61 highly enantioselective reactions are possible. For 
example, diazo compound 64 cyclised efficiently to give 65 in 
high ee and with good yield in the presence of a Rh catalyst 
(Scheme 14).62 This reaction was used in the synthesis of 
conocarpan 6663 and epi-cococarpon 67.64 Similarly, the Rh-
catalysed asymmetric C-H insertion reaction of 68 was used to 
construct the DHB core (69) of Serotobenine.65, 66
In a recent example, Yu employed a chiral auxiliary directed 
carbene insertion reaction to construct 71 containing the DHB 
skeleton of Lithospermic acid 73 (Scheme 15).67 This was 
then followed by a late-stage Pd-catalysed carboxylate-directed 
C-H alkenylation reaction to introduce the complete side chain 
of the natural product at the final stage.
An alternative strategy for C2–C3 bond formation is the 
asymmetric organocatalytic cyclisation of carboxyenones 74 
(Scheme 16).68 Generation of the mixed anhydride from the 
acid 74, followed by reaction with the catalyst 75 leads to 
ammonium enolate intermediate 76, which cyclises via reac-
tion with the pendant Michael acceptor. These reactions 
proceed with high diastereoselectivity and excellent enantiose-
lectivity to give the corresponding cis 2,3-disubstituted DHBs 
77 in good to excellent yield. This provides a useful asym-
metric method for accessing cis-subsituted DHB systems 
(e.g. 78–79) which can be difficult to obtain via many other 
approaches.
The formation of the C2–C3 bond by generation of an anion 
on the carbon adjacent to the oxygen atom is an unusual alter-
native strategy. This was accomplished by reaction of phenol 
80 with 81 to give α-silylthioether 82, which could be 
cyclised in the presence of fluoride to give a mixture of dia-
stereoisomers of the 2,3-disubtituted DHB 83 in good yield 
(Scheme 17).69
The C2–C3 bond has also been constructed photochemically. 
Benzophenone 84, bearing a prenyl ether subsituent was shown 
to cyclise under irradiation to give DHB 85 in 40% yield as a 
mixture of diastereoisomers (Scheme 18).70 However, the 
major product of this reaction was acetal 86.
7 Two-component cyclisation approaches
Concerted cyclisation approaches in which two bonds are 
formed in the same reaction are highly attractive, as subsi-
tutents can readily be varied at many different locations on 
Scheme 14 Total synthesis of DHB natural products using 
Rh-catalysed carbene insertion.
Scheme 15 Total synthesis of Lithospermic acid via carbene 
insertion and late-stage C-H activation.
Scheme 16 Organocatalytic asymmetric formation of 
cis-2,3-disubstituted DHBs.
Scheme 17 Fluoride-mediated carbanion cyclisation.
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the DHB ring system by changing the two components 
employed in the reaction. One such approach is the reaction of 
iminophenols 87 with carbonates 88 in the presence of a 
phosphine catalyst, to give the 3-amino DHBs 89 with good 
yield and moderate to high stereoselectivity (Scheme 19).71 
DHBs with two (90) or three (91) substituents on the oxygen 
heterocycle could be obtained.
An improved procedure was recently reported for the Pd-
catalysed reaction of 2-iodophenyl acetates 92 with dienes 93 
to give DHBs 94 (Scheme 20).72 A range of 2,2-disubstituted 
DHBs (e.g. 95) could be accessed in good yield, although the 
effect of substituents at all positions on the diene was not 
investigated simultaneously. Only two examples were reported 
in which more than one diastereoisomer can be formed, 
though these products were formed with high trans diastere-
oselectivity (e.g. 96).
In a related approach, aminophenols 97 were converted 
directly into trans-2,3-disubstituted DHBs 99 in a one-pot 
process (Scheme 21).73 Diazotisation of the aniline was 
followed by treatment with a palladium catalyst in the pres-
ence of a β-substituted styrene 98 to give DHBs 99. A range 
of electron rich styrenes 98 were used to access a variety of 
2,3-disubstituted DHBs (e.g. 100–101). This approach was 
used to construct a DHB intermediate in the synthesis of 
cinerins A-C, lignans isolated from Pleurothyrium cinereum 
which show platelet activating factor (PAF) antagonist 
activity.74
The oxidative dimerisation of caffeic acid esters 102 with 
silver(I) oxide has been applied to the synthesis of trans-
DHBs 103 in a biomimetic fashion in several reports (Scheme 
22).23,75–77 Oxidative coupling of the same substrates with Mn 
salts did not give DHBs, with benzoxanthenes and aryldihy-
dronaphthalenes being produced.78 This reaction has also been 
achieved biocatalytically. In a very recent example, the oxida-
tive dimerisation of related esters using crude peroxidase 
derived from onions has been reported, although the resulting 
products had no optical rotation.78
Arylmethyl cyclopropyl ketones 104 were shown to undergo 
ring-opening and condensation with ethyl acetoacetate 105 
in the presence of trimethysilyl triflate to give DHBs 106 in 
moderate yield (Scheme 23).79 The reaction is thought to 
proceed via ring opening of the cyclopropyl ketone to give a 
γ-hydroxyketone 107, which undergoes aldol condensation 
with 105 to give 108, followed by a second condensation 
to give 109, and finally cyclisation and condensation of the 
pendant hydroxyl group to give the DHB 106. Notably this 
involves the synthesis of both the benzene ring and the oxygen 
heterocycle in the same reaction.
Quinones and their derivatives have frequently been 
employed in DHB synthesis (Scheme 24). In a recent example, 
the reaction of quinone mono imine 110 with α,β-unsaturated 
hydrazone 111 was reported to give 2,2-disubstituted DHB 
112 in 90% yield.80 This compound was subsequently employed 
in a total synthesis of the α2-adrenergic receptor antagonist 
Efaroxan 14, and a range of related amino derivatives. The 
Scheme 18 Photochemical cyclisation approach to a DHB.
Scheme 19 Phosphine-catalysed reaction of iminophenols 
with O-Boc Bayliss-Hilman adducts.
Scheme 20 Pd-catalysed reaction of ortho-iodophenyl 
acetates with dienes.
Scheme 21 One-pot diazotization/Pd-catalysed cyclisation of 
2-aminophenols.
Scheme 22 Biomimetic oxidative dimerisation of a caffeic 
acid ester with AgO.
Scheme 23 A Me3SiOTf-mediated formation of DHBs from 
ethyl acetoacetate and arylmethyl cyclopropyl ketones.
JOURNAL OF CHEMICAL RESEARCH 2011 383
reaction of hydroquinone 113 with stilbene oxide 114 was 
reported to proceed well in the presence of BF3.OEt2, giving 
polysubstituted DHB 115 in good yield.81 This reaction was 
initially observed during the development of a method for 
benzofuran synthesis using the corresponding quinones. In 
a similar reaction, quinone 116 was reported to react with 
β-methylstyrenes 117 using catalytic BF3.OEt2 in PEG-400 to 
give DHBs 118–119 in moderate yield.82 
The copper or silver catalysed 3-component coupling of 
salicylaldehydes 119, alkynes 120 and piperidine 121 was 
found to give 3-amino DHBs 123 in good yield.83 The reaction 
proceeds via initial formation of propargylic amine 122. Metal-
catalysed cyclisation of the phenol onto the alkyne then takes 
place to give exclusively the Z-alkene, provided there is a 
heteroatom in the R-group on the alkyne (e.g. 124–125). The 
heteroatom was thought to be required in order to assist 
the transition-metal activation of the alkyne for cyclisation. 
Substrates which do not contain a heteroatom on the R group 
are able to undergo the initial reaction to give 122, but do not 
cyclise to the DHB.
Recently, two research groups have simultaneously reported 
an elegant approach to the antimalarial natural product Decur-
sivine 127, via photochemical rearrangement of dichloroamide 
126 (Scheme 26).84, 85 The reaction leads to diastereoselective 
formation of the fused lactam-DHB core of the natural product 
in a single photochemical reaction in moderate to good yield. 
This synthetic approach is considerably more concise than 
previous syntheses of the related natural product Serotobinine 
(Scheme 14).
8 Rearrangement reactions
DHB systems have occasionally been synthesised by rear-
rangement of other ring systems. This can provide a method to 
construct DHBs with unusual substitution patterns which may 
not be readily accessible by other means. For example, furans 
bearing a pendant alkynyl ether substituent 129 were shown to 
undergo rearrangement in the presence of catalytic AuCl3 to 
give 2,6,7-trisubsituted DHBs 130 (Scheme 27).86 The reaction 
is thought to proceed via formation of the tricyclic cyclopro-
pane 131, which undergoes ring opening and then re-
cyclisation to the benzene epoxide 133. Rearrangement of 
this intermediate then gives the polysubstituted DHB 130 in 
moderate yield over two steps from the dichlorovinyl ether 
128.
A Tl(NO3)3 mediated ring contraction87 of 136, was recently 
employed in a synthesis of the proposed Lawsonicin skeleton, 
during a study which led to a revision of the original structural 
assignment of the natural product (Scheme 28).88 The reaction 
Scheme 24 Use of quinone derivatives in DHB synthesis.
Scheme 25 3-component reaction of piperidine, 
salicylaldehyde and an alkyne in the presence of CuI.
Scheme 26 Photochemical synthesis of the antimalarial DHB 
Decursivine.
Scheme 27 Au-catalysed rearrangement of furans bearing 
an alkynyl ether.
Scheme 28 Tl(NO3)3-mediated ring-contraction to generate a 
DHB.
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is thought to involve acid-catalysed formation of the enol ether 
137, which reacts with the thallium salt and then undergoes 
a ring-contraction of intermediate 138 to give 139 via aryl 
migration with concomitant reduction of the thallium from 
Tl(III) to Tl(I).
In the presence of Lewis acids, 3-aminodihydrobenzopyrans 
140 were recently reported to rearrange to the corresponding 
2-aminomethyl DHBs 141 (Scheme 29).89 In a brief study, 
boron tribromide was found to be the most effective Lewis 
acid for inducing this transformation.
As can be seen from this article, there have been numerous 
recent developments in the chemical synthesis of DHBs, many 
of which provide excellent control over the relative or absolute 
stereochemistry of substituents on the saturated oxygen het-
erocycle. It should be noted that most of the synthetic strate-
gies outlined above enable DHBs to be constructed via short 
reaction sequences from readily available starting materials. 
Such methods enable the synthesis of even very highly com-
plex DHB systems to be readily achieved, with excellent scope 
for structural variation on the DHB scaffold. The diverse bio-
logical activities exhibited by both synthetic and naturally 
occurring DHBs suggest that they have great potential as lead 
compounds in the study of biological processes and the treat-
ment of disease. It is hoped that this article, by providing a 
general overview of the synthetic strategies available, will 
serve to stimulate greater interest in the study of DHBs in 
medicinal chemistry, and further improvement of the synthetic 
strategies available for constructing them.
I would like to thank the EPSRC for supporting my research 
through the award of an Advanced Research Fellowship (EP/
E052789/1).
Received 17 May 2011; accepted 17 June 2011
Paper 1100702 doi: 10.3184/174751911X13096980701749
Published online: 15 July 2011
References
 1 S.P. Verevkin, V.N. Emel’yanenko, A.A. Pimerzin and E.E. Vishnevskaya, 
J. Phys. Chem. A, 2011, 115, 1992.
 2 I.S. Lee, H.-J. Kim, U.-J. Youn, Q.-C. Chen, J.-P. Kim, D.T. Ha, T.M. Ngoc, 
B.-S. Min, S.-M. Lee, H.-J. Jung, M.-K. Na and K.-H. Bae, Helv. Chim. 
Act., 2010, 93, 272.
 3 W.-S. Feng, X.-Y. Zang, X.-K. Zheng, Y.-Z. Wang, H. Chen and Z. Li, 
J. Asian Nat. Prod. Res., 2010, 12, 557.
 4 P.X. Lai, Q.L. Ma and K.H. Row, J. Chem. Res., 2010, 514.
 5 S.K. Manna, J.S. Bose, V. Gangan, N. Raviprakash, T. Navaneetha, P.B. 
Raghavendra, B. Babajan, C.S. Kumar and S.K. Jain, J. Biol. Chem., 2010, 
285, 22318.
 6 D.T. Ha, T.M. Ngoc, I. Lee, Y.M. Lee, J.S. Kim, H. Jung, S. Lee, M. Na and 
K. Bae, J. Nat. Prod., 2009, 72, 1465.
 7 E.D. Coy, L.E. Cuca and M. Sefkow, Bioorg. Med. Chem. Lett., 2009, 19, 
6922.
 8 S. Shang and S. Long, Chem. Nat. Compounds, 2008, 44, 186. 
 9 J.-A. Duan, L. Wang, S. Qian, S. Su and Y. Tang, Arch. Pharmacol Res., 
2008, 31, 965.
10 S. Di Micco, F. Mazué, C. Daquino, C. Spatafora, D. Delmas, N. Latruffe, 
C. Tringali, R. Riccio and G. Bifulco, Org. Biomol. Chem., 2011, 9, 701.
11 H.-Y. Huang, T. Ishikawa, C.-F. Peng, I.-L. Tsai and I.-S. Chen, J. Nat. 
Prod., 2008, 71, 1146.
12 H. Zhang, S. Qiu, P. Tamez, G. T. Tan, Z. Aydogmus, N. Van Hung, N.M. 
Cuong, C. Angerhofer, D.D. Soejarto, J.M. Pezzuto and H.H.S. Fong, 
Pharm. Biol., 2002, 40, 221.
13 M. Saito, M. Ueo, S. Kametaka, O. Saigo, S. Uchida, H. Hosaka, K. 
Sakamoto, T. Nakahara, A. Mori and K. Ishii, Biolog. Pharm. Bull., 2008, 
31, 1959.
14 S.F. Kouam, S.N. Khan, K. Krohn, B.T. Ngadjui, D.G.W.F. Kapche, D.B. 
Yapna, S. Zareem, A.M.Y. Moustafa and M.I. Choudhary, J. Nat. Prod., 
2006, 69, 229.
15 T. Wakimoto, K. Miyata, H. Ohuchi, T. Asakawa, H. Nukaya, Y. Suwa and 
T. Kan, Org. Lett., 2011, 13, 2789. 
16 A. Stoessl, Tetrahedron Lett., 1966, 7, 2849. 
17 A. Stoessl, Tetrahedron Lett., 1966, 7, 2287.
18 Y.-W. Chin, H.-B. Chai, W.J. Keller and A.D. Kinghorn, J. Agric. Food 
Chem., 2008, 56, 7759.
19 Z. Huang, Q. Cui, L. Xiong, Z. Wang, K. Wang, Q. Zhao, F. Bi and 
Q. Wang, J. Agric. Food Chem., 2009, 57, 2447-2456.
20 N. Negoro, S. Sasaki, S. Mikami, M. Ito, M. Suzuki, Y. Tsujihata, R. Ito, 
A. Harada, K. Takeuchi, N. Suzuki, J. Miyazaki, T. Santou, T. Odani, 
N. Kanzaki, M. Funami, T. Tanaka, A. Kogame, S. Matsunaga, T. Yasuma 
and Y. Momose, Acs Med. Chem. Lett., 2010, 1, 290-294.
21 W. Chen, X.-D. Yang, Y. Li, L.-J. Yang, X.-Q. Wang, G.-L. Zhang and 
H.-B. Zhang, Org. Biomol Chem., 2011, DOI: 10.1039/C1OB05116D.
22 R.P. Tripathi, A.K. Yadav, A. Ajay, S.S. Bisht, V. Chaturvedi and S.K. 
Sinha, Eur. J. Med. Chem., 2010, 45, 142.
23 S. Van Miert, S. Van Dyck, T.J. Schmidt, R. Brun, A. Vlietinck, G. Lemiere 
and L. Pieters, Biorg. Med. Chem., 2005, 13, 661.
24 J.E. Frampton, Drugs, 2009, 69, 2463.
25 C.B. Chapleo, P.L. Myers, R.C.M. Butler, J.A. Davis, J.C. Doxey, S.D. 
Higgins, M. Myers, A.G. Roach, C.F.C. Smith, J. Med. Chem., 1984, 27, 
570.
26 F. Bertolini and M. Pineschi, Org. Prep. Proc. Int., 2009, 41, 385.
27 H. Jiang, T. Sugiyama, A. Hamajima and Y. Hamada, Adv. Synth. Catal., 
2011, 353, 155.
28 A. Chatterjee and S.S. Mitra, J. Am. Chem. Soc., 1949, 71, 606.
29 S.K. Dinda, S.K. Das and G. Panda, Synthesis, 2009, 1886.
30 F.A. Macías, R.M. Varela, A. Torres and J.M.G. Molinillo, J. Nat. Prod., 
1999, 62, 1636.
31 S.K. Das and G. Panda, Tetrahedron, 2008, 64, 4162-4173.
32 C. Ito, S. Katsuno, Y. Kondo, H.T.-W. Tan and H. Furukawa, Chem. Pharm. 
Bull., 2000, 48, 339.
33 J. Takashima and A. Ohsaki, J. Nat. Prod., 2002, 65, 1843.
34 S. Kantevari, D. Addla and B. Sridhar, Synthesis, 2010, 3745.
35 J. Seo, S.S. Lee, W.-T. Gong and K. Hiratani, Tetrahedron Lett., 2008, 49, 
3770.
36 K. Okuma, T. Yasuda, I. Takeshita, K. Shioji and Y. Yokomori, Tetrahedron, 
2007, 63, 8250.
37 B.S. Samant and S.S. Bhagwat, Chinese J. Catal., 2011, 32, 231.
38 Q.Z. Zhou, C.L. He and Z.C. Chen, Chinese Chem. Lett., 2008, 19, 661.
39 B. Gabriele, R. Mancuso and G. Salerno, J. Org. Chem., 2008, 73, 7336.
40 J. Mangas-Sánchez, E. Busto, V. Gotor-Fernández and V. Gotor, Org. Lett., 
2010, 12, 3498.
41 M. Uyanik, H. Okamoto, T. Yasui and K. Ishihara, Science, 2010, 328, 
1376-1379.
42 S.-I. Kuwabe, K.E. Torraca and S.L. Buchwald, J. Am. Chem. Soc., 2001, 
123, 12202. 
43 M. Palucki, J.P. Wolfe and S.L. Buchwald, J. Am. Chem. Soc., 1996, 118, 
10333.
44 C. Pan, Z. Ma, J. Yu, Z. Zhang, A. Hui and Z. Wang, Synlett, 2005, 1922.
45 J. Zhu, B.A. Price, S.X. Zhao and P.M. Skonezny, Tetrahedron Lett., 2000, 
41, 4011.
46 C. Körner, P. Starkov and T.D. Sheppard, J. Am. Chem. Soc., 2010, 132, 
5968.
47 J.X. Qiao and P.Y.S. Lam, Synthesis, 2010, 829.
48 X. Wang, Y. Lu, H.-X. Dai and J.-Q. Yu, J. Am. Chem. Soc., 2010, 132, 
12203.
49 Y. Komine, A. Kamisawa and K. Tanaka, Org. Lett., 2009, 11, 2361.
50 J.E. Imbriglio and J.D. Rainier, Tetrahedron Lett, 2001, 42, 6987.
51 T. Mino, Y. Naruse, S. Kobayashi, S. Oishi, M. Sakamoto and T. Fujita, 
Tetrahedron Lett., 2009, 50, 2239.
52 B.M. Trost, D.A. Brinhley and S.M. Silverman, J. Am. Chem. Soc., 2011, 
DOI: 10.1021/ja201181g.
53 C. Fressigné, A.-L. Girard, M. Durandetti and J. Maddaluno, Chem. — 
A Eur. J., 2008, 14, 5159.
54 H. Sundén and R. Olsson, Org. Biomol. Chem., 2010, 8, 4831.
55 F.A. Siqueira, J.G. Taylor and C.R.D. Correia, Tetrahedron Lett., 2010, 51, 
2102.
56 M. Szlosek-Pinaud, P. Diaz, J. Martinez and F. Lamaty, Tetrahedron, 2007, 
63, 3340.
57 H.S. Lee, K.H. Kim, J.W. Lim and J.N. Kim, Bull. Korean Chem. Soc., 
2011, 32, 1083.
58 H.M.L. Davies and T. Hansen, J. Am. Chem. Soc., 1997, 119, 9075. 
59 H.M.L. Davies, T. Hansen and M.R. Churchill, J. Am. Chem. Soc., 2000, 
122, 3063.
60 H.M.L. Davies, M.V.A. Grazini and E. Aouad, Org. Lett., 2001, 3, 1475.
61 W. Kurosawa, T. Kan and T. Fukuyama, Synlett, 2003, 1028.
62 Y. Natori, H. Tsutsui, N. Sato, S. Nakamura, H. Nambu, M. Shiro and 
S. Hashimoto, J. Org. Chem., 2009, 74, 4418.
Scheme 29 Ring contraction of a 3-aminodihydrobenzopyran 
with BBr3.
JOURNAL OF CHEMICAL RESEARCH 2011 385
63 T. Hayashi and R.H. Thomson, Phytochemistry, 1975, 14, 1085.
64 P.J.C. Benevides, P. Sartorelli and M.J. Kato, Phytochemistry, 1999, 52, 
339.
65 Y. Koizumi, H. Kobayashi, T. Wakimoto, T. Furuta, T. Fukuyama and 
T. Kan, J. Am. Chem. Soc., 2008, 130, 16854.
66 H. Sato, H. Kawagishi, T. Nishimura, S. Yoneyama, Y. Yoshimoto, S. 
Sakamura, A. Furusaki, S. Katsuragi and T. Matsumoto, Agric. Biol. Chem., 
1985, 49, 2969.
67 D.-H. Wang and J.-Q. Yu, J. Am. Chem. Soc., 2011, 133, 5767.
68 D. Belmessieri, L.C. Morrill, C. Simal, A.M.Z. Slawin and A.D. Smith, 
J. Am. Chem. Soc., 2011, 133, 2714.
69 A. Capperucci, A. Degl’Innocenti, T. Nocentini and S. Pollicino, J. Sulfur 
Chem., 2009, 30, 319.
70 R. Pérez-Ruiz, O. Hinze, J.-M. Neudofl, D. Blunk, H. Görner and A.G. 
Griesbeck, Photochem. Photobiol. Sci., 2008, 7, 782.
71 P. Xie, Y. Huang and R. Chen, Org. Lett., 2010, 12, 3768.
72 R.V. Rozhkov and R.C. Larock, J. Org. Chem., 2010, 75, 4131.
73 E.D. Coy, L. Jovanovic and M. Sefkow, Org. Lett., 2010, 12, 1976.
74 E.D. Coy, L.E. Cuca and M. Sefkow, Org. Biomol. Chem., 2010, 8, 2003.
75 S.M.O. Van Dyck, G.L.F. Lemière, T.H.M. Jonckers and R. Dommisse, 
Molecules, 2000, 5, 153. 
76 L. Pieters, S. Van Dyck, M. Gao, R. Bai, E. Hamel, A. Vlietinck and 
G. Lemière, J. Med. Chem., 1999, 42, 5475.
77 C. Daquino, A. Rescifina, C. Spatafora and C. Tringali, Eur. J. Org. Chem., 
2009, 6289.
78 S. Moussouni, M.-L. Saru, E. Ioannou, M. Mansour, A. Detsi, V. Roussis 
and P. Kefalas, Tetrahedron Lett., 2011, 52, 1165.
79 M. Shi, X.-Y. Tang and Y.-H. Yang, J. Org. Chem., 2008, 73, 5311.
80 T. Lomberget and R. Barret, Tetrahedron Lett., 2008, 49, 715.
81 K. Kokubo, K. Harada, E. Mochizuki and T. Oshima, Tetrahedron Lett., 
2010, 51, 955.
82 V.V. Kouznetsov, D.R.M. Arenas and A.R.R. Bohórquez, Tetrahedron Lett., 
2008, 49, 3097.
83 R.-V. Nguyen and C.-J. Li, Synlett, 2008, 1897.
84 M. Mascal, K.V. Modes and A. Durmus, Angew. Chem. Int. Ed., 2011, 
10.1002/anie.201006423.
85 H. Qin, Z. Xu, Y. Cui and Y. Jia, Angew. Chem. Int. Ed., 2011, 10.1002/
anie.201100495.
86 A.S.K. Hashmi, M. Rudolph, J.W. Bats, W. Frey, F. Rominger and T. Oeser, 
Chem.-A Eur. J., 2008, 14, 6672.
87 M.S. Khanna, O.V. Singh, C.P. Garg and R.P. Kapoor, Synth. Commun., 
1993, 23, 585.
88 J. Meng, T. Jiang, H.A. Bhatti, B.S. Siddiqui, S. Dixon and J.D. Kilburn, 
Org. Biomol. Chem., 2010, 8, 107.
89 S. Chasset-Boyé, M.C. Viaud-Massuard, F. Suzenet and G. Guillaumet, 
Rev. Chim., 2010, 61, 404.
